WallStSmart

Ecolab Inc (ECL)vsLyondellBasell Industries NV (LYB)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

LyondellBasell Industries NV generates 85% more annual revenue ($31.19B vs $16.84B). ECL leads profitability with a 12.6% profit margin vs -1.1%. LYB appears more attractively valued with a PEG of 1.53. LYB earns a higher WallStSmart Score of 65/100 (C+).

ECL

Buy

53

out of 100

Grade: C-

Growth: 4.7Profit: 7.0Value: 3.7Quality: 5.5
Piotroski: 3/9Altman Z: 2.17

LYB

Buy

65

out of 100

Grade: C+

Growth: 6.7Profit: 4.5Value: 4.3Quality: 5.0
Piotroski: 2/9Altman Z: 1.57
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ECL.

LYBOvervalued (-7.3%)

Margin of Safety

-7.3%

Fair Value

$55.45

Current Price

$63.69

$8.24 premium

UndervaluedFair: $55.45Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ECL2 strengths · Avg: 9.0/10
Market CapQuality
$80.38B9/10

Large-cap with strong market position

Return on EquityProfitability
21.1%9/10

Every $100 of equity generates 21 in profit

LYB3 strengths · Avg: 8.7/10
EPS GrowthGrowth
396.0%10/10

Earnings expanding 396.0% YoY

Price/BookValuation
1.9x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
19.8%8/10

19.8% revenue growth

Areas to Watch

ECL4 concerns · Avg: 3.5/10
P/E RatioValuation
38.3x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
3.3%4/10

3.3% earnings growth

Debt/EquityHealth
1.373/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

LYB4 concerns · Avg: 3.5/10
PEG RatioValuation
1.534/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.574/10

Distress zone — elevated risk

Debt/EquityHealth
1.333/10

Elevated debt levels

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ECL

The strongest argument for ECL centers on Market Cap, Return on Equity.

Bull Case : LYB

The strongest argument for LYB centers on EPS Growth, Price/Book, Revenue Growth. Revenue growth of 19.8% demonstrates continued momentum.

Bear Case : ECL

The primary concerns for ECL are P/E Ratio, EPS Growth, Debt/Equity.

Bear Case : LYB

The primary concerns for LYB are PEG Ratio, Altman Z-Score, Debt/Equity.

Key Dynamics to Monitor

ECL profiles as a value stock while LYB is a growth play — different risk/reward profiles.

ECL carries more volatility with a beta of 0.89 — expect wider price swings.

LYB is growing revenue faster at 19.8% — sustainability is the question.

ECL generates stronger free cash flow (489M), providing more financial flexibility.

Bottom Line

LYB scores higher overall (65/100 vs 53/100) and 19.8% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Ecolab Inc

BASIC MATERIALS · SPECIALTY CHEMICALS · USA

Ecolab Inc., headquartered in St. Paul, Minnesota, is an American corporation that develops and offers services, technology and systems that specialize in water treatment, purification, cleaning and hygiene in a wide variety of applications. It helps organizations both private market as well as public treat their water, not only for drinking directly, but also for use in food, healthcare, hospitality related safety and industry.

LyondellBasell Industries NV

BASIC MATERIALS · SPECIALTY CHEMICALS · USA

LyondellBasell Industries N.V. (NYSE: LYB) is a Dutch-domiciled multinational chemical company with American and British roots, incorporated in the Netherlands, with U.S. operations headquarters in Houston, Texas, and offices in London, UK. The company is the largest licensor of polyethylene and polypropylene technologies. It also produces ethylene, propylene, polyolefins, and oxyfuels.

Want to dig deeper into these stocks?